Oral Nadolol for the Treatment of Adults With Mild Asthma

Completed · Phase 1/Phase 2

Conditions studied: Asthma

In brief

The purpose of this study is to confirm previous observations in asthmatics that chronic nadolol treatment reduces asthmatic airway hyper-responsiveness.

Key facts

Study ID

NCT00670267

Run by

Invion, Inc.

People needed

10

Starts

2007-01-01

Expected to finish

2009-06-01

Last updated by the study team

2016-05-11

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Pre-bronchodilator FEV1 80% or greater than the predicted value.
• PC20 FEV1 ≤4 mg/ml on methacholine challenge test.
• Blood Pressure ≥ 100/65mm Hg.
• Pulse rate ≥ 60 beats/min.
• No significant health issues.
• Non-smoker or X-smoker < 10 pack/year.

You may not qualify if…

• History of upper/lower respiratory tract infection or asthma exacerbation within 6 weeks of first baseline visit.
• Currently diagnosed with chronic obstructive pulmonary disease (COPD).
• Used any oral or inhaled corticosteroids within 4 weeks of the first baseline visit.

Where it is running

• Baylor College of Medicine — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.